79 related articles for article (PubMed ID: 22244666)
21. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy and targeted agents for thymic malignancies.
Girard N
Expert Rev Anticancer Ther; 2012 May; 12(5):685-95. PubMed ID: 22594902
[TBL] [Abstract][Full Text] [Related]
23. Promising molecular targets in ovarian cancer.
Blagden S; Gabra H
Curr Opin Oncol; 2009 Sep; 21(5):412-9. PubMed ID: 19553815
[TBL] [Abstract][Full Text] [Related]
24. Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies.
Rowinsky EK
J Clin Oncol; 2003 May; 21(10 Suppl):175s-186s. PubMed ID: 12743132
[TBL] [Abstract][Full Text] [Related]
25. Targeted therapies in the treatment of gastric cancer.
Ngeow J; Tan IB; Choo SP
Asia Pac J Clin Oncol; 2011 Sep; 7(3):224-35. PubMed ID: 21884434
[TBL] [Abstract][Full Text] [Related]
26. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Pang RW; Poon RT
Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
[TBL] [Abstract][Full Text] [Related]
27. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Markman M
Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
[TBL] [Abstract][Full Text] [Related]
28. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
29. [New drugs and targeted therapeutic agents in ovarian cancer].
de La Motte Rouge T; Petrella MC; Michels J; Even C; Balleyguier C; Duclos J; Mazeron R; Morice P; Pautier P; Lhommé C
Bull Cancer; 2009 Dec; 96(12):1215-24. PubMed ID: 19919916
[TBL] [Abstract][Full Text] [Related]
30. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors.
Newton HB
Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572
[TBL] [Abstract][Full Text] [Related]
31. Targeted cancer therapy: promise and reality.
Klein S; Levitzki A
Adv Cancer Res; 2007; 97():295-319. PubMed ID: 17419951
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel anticancer therapeutics targeting the PI3K/Akt/mTOR pathway.
Maira SM; Furet P; Stauffer F
Future Med Chem; 2009 Apr; 1(1):137-55. PubMed ID: 21426073
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapies in breast cancer: where are we now?
Di Cosimo S; Baselga J
Eur J Cancer; 2008 Dec; 44(18):2781-90. PubMed ID: 19013786
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
35. Targeting the EGFR and the PKB pathway in cancer.
Klein S; Levitzki A
Curr Opin Cell Biol; 2009 Apr; 21(2):185-93. PubMed ID: 19216065
[TBL] [Abstract][Full Text] [Related]
36. Targeting the PI3K-Akt pathway in kidney cancer.
Park JY; Lin PY; Weiss RH
Expert Rev Anticancer Ther; 2007 Jun; 7(6):863-70. PubMed ID: 17555396
[TBL] [Abstract][Full Text] [Related]
37. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
[TBL] [Abstract][Full Text] [Related]
38. [New therapeutic approaches in glioblastomas].
Le Guilloux J; Carpentier AF
Rev Neurol (Paris); 2008; 164(6-7):554-9. PubMed ID: 18565354
[TBL] [Abstract][Full Text] [Related]
39. PARP inhibitors in cancer therapy: an update.
Papeo G; Casale E; Montagnoli A; Cirla A
Expert Opin Ther Pat; 2013 Apr; 23(4):503-14. PubMed ID: 23379721
[TBL] [Abstract][Full Text] [Related]
40. Targeting PI3K signaling as a therapeutic approach for colorectal cancer.
Zhang J; Roberts TM; Shivdasani RA
Gastroenterology; 2011 Jul; 141(1):50-61. PubMed ID: 21723986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]